Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary-Reference-Cited by-同舟云学术

Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary

Published:2013-09 Issue:2 Volume:2 Page:264-266
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Kaló Zoltán,Bodrogi József,Boncz Imre,Dózsa Csaba,Jóna Gabriella,Kövi Rita,Pásztélyi Zsolt,Sinkovits Balázs

Publisher

Elsevier BV

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference8 articles.

1. Issues for countries considering introducing the “fourth hurdle”: the case of Hungary;Gulácsi;Int J Technol Assess Health Care,2004

2. Development of health economics in Hungary between 1990-2006;Boncz;Eur J Health Econ,2006

3. Health economics and health technology assessment in Central and Eastern Europe: a dose of reality;Gulácsi;Eur J Health Econ,2012

4. Central Statistical Office of Hungary. Per capita gross domestic product (GDP) (1995-), 2012. Available from: http://www.ksh.hu/docs/eng/xstadat/xstadat_annual/i_qpt016.html. [Accessed November 18, 2012].

5. EBM TUDOR 2012. Available from: http://tudor.szote.u-szeged.hu/webeng/what/whatbe.php. [Accessed November 18, 2012].

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The long-term effect of generic price competition on the Hungarian statin market;BMC Health Services Research;2023-05-06

2. Capacity Building for Health Technology Assessment in Jordan: Institutionalization and Its Use in Pricing and Reimbursement Decisions;Value in Health Regional Issues;2022-11

3. Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?;Applied Health Economics and Health Policy;2022-01-18

4. A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges;Frontiers in Pharmacology;2021-11-12

5. Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries—A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses;Frontiers in Pharmacology;2020-08-14